Antiallodynic Effect of Piperine in Neuropathic Rats
- PDF / 454,245 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 53 Downloads / 163 Views
ORIGINAL ARTICLE
Antiallodynic Effect of Piperine in Neuropathic Rats Luis Arturo Sánchez-Trujillo 1 & Jorge Luis Mendoza-Monroy 1 & Héctor Isaac Rocha-González 2 Geovanna Nallely Quiñonez-Bastidas 1,2 & Jose Luis Balderas-López 1 & Andrés Navarrete 1
&
Received: 13 January 2020 / Accepted: 24 February 2020 # Sociedade Brasileira de Farmacognosia 2020
Abstract Neuropathic pain is a disabling syndrome difficult to manage. Currently, pharmacological treatment of neuropathic patients provides an unsatisfactory relief of pain. Recent reports suggested that piperine has anti-inflammatory and antinociceptive effects. Therefore, the aim of this study was to investigate the antiallodynic effect of piperine, as well as the possible antinociceptive mechanism involved in its antiallodynic effect. Piper nigrum L., Piperaceae, was used to extract the piperine. Spinal nerve ligation L5/L6 model was used to induce allodynia in rats. Intraperitoneal administration of increasing doses of piperine (3.1–100 mg/kg) reduced allodynia in rats. The administration of capsazepine (selective TRPV1 antagonist, 5 and 30 μg/i.t.) and bicuculline (GABAA antagonist, 3 and 30 μg/ i.t.), but not SKF-96365 (TRPC antagonist, 3 and 30 μg/i.t.), prevented the piperine-induced (56 mg/kg, i.p.) antiallodynic effect in a dose-dependent manner. HC-030031 (selective TRPA1 antagonist, 3 and 30 μg/i.t.) avoided only partially piperine-induced (56 mg/kg, i.p.) antiallodynic effect. Data suggest that piperine induces antiallodynic effect in neuropathic rats, and its antiallodynic effect involves the activation of TRPV1 and GABAA receptors. Piperine could be useful to treat neuropathic pain in human beings. Keywords Allodynia . GABAA receptors . Neuropathic pain . Piperine . TRPV1 receptor
Introduction Neuropathic pain is caused by a lesion or disease of the somatosensory system, including peripheral fibers (Aβ, Aδ, and C fibers) and central neurons (Jensen et al. 2011). It is widely recognized as a public problem of health, which has been increased in the past few decades (Abbott et al. 2011). Prevalence of neuropathic pain in worldwide is uncertain; however, epidemiological studies estimate that 6.9–10% of population shows pain with neuropathic Electronic supplementary material The online version of this article (https://doi.org/10.1007/s43450-020-00047-z) contains supplementary material, which is available to authorized users. * Geovanna Nallely Quiñonez-Bastidas [email protected] * Andrés Navarrete [email protected] 1
Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, Ciudad Universitaria, Coyoacán, Mexico City, Mexico
2
Sección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Mirón s/n, 11340 Mexico City, Mexico
characteristics (Van Hecke et al. 2014). Neuropathic pain is a complex syndrome and difficult to treat due to its multifactorial pathophysiology. To date, pharmacological management not only is unsatisfactory, but al
Data Loading...
